(Q43146147)

14 November 2017

title

Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? (English)

1 reference

14 November 2017

1 reference

7

H P Kalofonos

0 references

author name string

A G Antonacopoulou

1

1 reference

14 November 2017

A A Argyriou

2

1 reference

14 November 2017

C D Scopa

3

1 reference

14 November 2017

A Kottorou

4

1 reference

14 November 2017

A Kominea

5

1 reference

14 November 2017

S Peroukides

6

1 reference

14 November 2017

H P Kalofonos

7

1 reference

14 November 2017

publication date

23 February 2010

1 reference

European Journal of Neurology

14 November 2017

published in

1 reference

14 November 2017

volume

17

1 reference

14 November 2017

issue

7

1 reference

14 November 2017

page(s)

963-968

1 reference

A review on oxaliplatin-induced peripheral nerve damage.

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Integrins: bidirectional, allosteric signaling machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

A prospective study of suramin-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

A review of oxaliplatin and its clinical use in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Analysis of cytotoxicities of platinum compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Oxaliplatin-induced neurotoxicity and the development of neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Progressive paresthesias after cessation of therapy with very high-dose cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Emerging role of mitogen-activated protein kinases in peripheral neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Role of N-methyl-D-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Role of MAPKs in platinum-induced neuronal apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.02966.X

10.1111/J.1468-1331.2010.02966.X

21 January 2018

Identifiers

DOI

1 reference

14 November 2017

1 reference